Electronic Acknowledgement Receipt				
EFS ID:	1467680			
Application Number:	10551501			
International Application Number:				
Confirmation Number:	8326			
Title of Invention:	Biphenylcarboxylic amide derivatives as p38 kinase inhibitors			
First Named Inventor/Applicant Name:	Nicola Mary Aston			
Customer Number:	20462			
Filer:	Dara L. Dinner/Christina Boyer			
Filer Authorized By:	Dara L. Dinner			
Attorney Docket Number:	PB60196			
Receipt Date:	26-JAN-2007			
Filing Date:	25-MAY-2006			
Time Stamp:	11:36:52			
Application Type:	U.S. National Stage under 35 USC 371			

Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$450
RAM confirmation Number	1425
Deposit Account	192570

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part /.zip	Pages (if appl.)				
1		60196oa1.pdf	149306	yes	18				
	Multipart Description/PDF files in .zip description								
	Document De	scription	Start	End					
	Amendment - After No	n-Final Rejection	1	1					
	Claims	1	2	13					
	Applicant Arguments/Remarks Made in an Amendment		14	16					
	Terminal Disclaimer Filed		17	18					
Warnings:			•						
Information	:								
2	Information Disclosure Statement (IDS) Filed	IDSJan07.pdf	74258	no	4				
Warnings:									
Information	1								
This is not an	USPTO supplied IDS fillable form								
3	Information Disclosure Statement (IDS) Filed	PTO1449formJan07.pdf	169706	no	4				
Warnings:									
Information	1								
This is not an	USPTO supplied IDS fillable form								
4	Foreign Reference	WO06110173.pdf	5956914	no	130				
Warnings:									
Information									
5	Foreign Reference	JP11218884.pdf	2983981	no	142				
Warnings:									
Information									
6	Foreign Reference	wo9857934.pdf	7566193	no	165				
Warnings:									

Information:						
7	NPL Documents	CourtenyBioorgMedChem20 04.pdf	273935	no	5	
Warnings:						
Information:						
8	NPL Documents	FosterDrugNewsPersp.pdf	216676	no	10	
Warnings:						
Information:						
9	NPL Documents	HenryBioorgMedChem1998. pdf	299003	no	6	
Warnings:		'				
Information:						
10	NPL Documents	MarinBlood98_3.pdf	171078	no	7	
Warnings:						
Information:						
11	NPL Documents	HerlaarMolecularMedicineTo day5.pdf	261737	no	9	
Warnings:						
Information:						
12	Fee Worksheet (PTO-06)	fee-info.pdf	8180	no	2	
Warnings:		1				
Information:						
	Total Files Size (in bytes): 18130967					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/IDO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filling Receipt, in due course.